These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 8445943

  • 1. Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia.
    Kornblau SM, Cortes-Franco J, Estey E.
    Leukemia; 1993 Mar; 7(3):378-83. PubMed ID: 8445943
    [Abstract] [Full Text] [Related]

  • 2. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY, Yang LJ, Xu B, Liu XL, Zheng WY, Zhang Y, Huang F, Sun J, Liu QF.
    Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
    [Abstract] [Full Text] [Related]

  • 3. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W.
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [Abstract] [Full Text] [Related]

  • 4. Phase I study of a continuous infusion of high-dose ara-C in conjunction with a fixed dose of 2'-deoxycytidine (IND 28108) in patients with refractory leukemia: an interim report.
    Grant S, Baker M, Bhalla K.
    Leukemia; 1993 Dec; 7(12):1933-8. PubMed ID: 8255091
    [Abstract] [Full Text] [Related]

  • 5. [Induction of Ph-negative normal clone and long-term survival by combined treatment with G-CSF plus middle dose cytosine arabinoside for patients with chronic myeloid leukemia in blastic transformation].
    Katagiri T, Miyazawa K, Uchida Y, Hayashi S, Iwama H, Shyohji N, Kawakubo K, Shimamoto T, Inatomi Y, Kuriyama Y, Yaguchi M, Nehashi Y, Ohyashiki K, Toyama K.
    Rinsho Ketsueki; 1998 Dec; 39(12):1149-56. PubMed ID: 10028846
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
    Avramis VI, Wiersma S, Krailo MD, Ramilo-Torno LV, Sharpe A, Liu-Mares W, Kowck R, Reaman GH, Sato JK.
    Clin Cancer Res; 1998 Jan; 4(1):45-52. PubMed ID: 9516951
    [Abstract] [Full Text] [Related]

  • 7. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.
    Kreis W, Budman DR, Chan K, Allen SL, Schulman P, Lichtman S, Weiselberg L, Schuster M, Freeman J, Akerman S.
    Leukemia; 1991 Nov; 5(11):991-8. PubMed ID: 1961042
    [Abstract] [Full Text] [Related]

  • 8. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V, Estey E, Du M, Keating MJ, Plunkett W.
    Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
    [Abstract] [Full Text] [Related]

  • 9. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G, Graf N, Hasan C, Ackermann M, Breu H, Zernikow B, Bode U.
    Klin Padiatr; 1996 Sep; 208(4):229-35. PubMed ID: 8926688
    [Abstract] [Full Text] [Related]

  • 10. Idarubicin in blastic crisis of chronic myelogenous leukemia.
    Lambertenghi-Deliliers G, Annaloro C, Cortellaro M, Pozzoli E, Oriani A, Polli EE.
    Haematologica; 1991 Sep; 76(5):406-8. PubMed ID: 1806446
    [Abstract] [Full Text] [Related]

  • 11. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia.
    Clavio M, Carrara P, Miglino M, Pierri I, Canepa L, Balleari E, Gatti AM, Cerri R, Celesti L, Vallebella E, Sessarego M, Patrone F, Ghio R, Damasio E, Gobbi M.
    Haematologica; 1996 Sep; 81(6):513-20. PubMed ID: 9009438
    [Abstract] [Full Text] [Related]

  • 12. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
    Yalman N, Sarper N, Devecioğlu O, Anak S, Eryilmaz E, Can M, Yenilmez H, Ağaoğlu L, Gedikoğlu G.
    Turk J Pediatr; 2000 Sep; 42(3):198-204. PubMed ID: 11105617
    [Abstract] [Full Text] [Related]

  • 13. High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis.
    Barone S, Baer MR, Sait SN, Lawrence D, Block AW, Wetzler M.
    Am J Hematol; 2001 Jun; 67(2):119-24. PubMed ID: 11343384
    [Abstract] [Full Text] [Related]

  • 14. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R, Pecci A, Rossi G, Pelizzari AM, Giusto M, Tinelli C, Ascari E.
    Haematologica; 1997 Jun; 82(6):660-3. PubMed ID: 9499664
    [Abstract] [Full Text] [Related]

  • 15. Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia.
    Suki S, Kantarjian H, Gandhi V, Estey E, O'Brien S, Beran M, Rios MB, Plunkett W, Keating M.
    Cancer; 1993 Oct 01; 72(7):2155-60. PubMed ID: 8374873
    [Abstract] [Full Text] [Related]

  • 16. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
    Kornblau SM, Gandhi V, Andreeff HM, Beran M, Kantarjian HM, Koller CA, O'Brien S, Plunkett W, Estey E.
    Leukemia; 1996 Oct 01; 10(10):1563-9. PubMed ID: 8847890
    [Abstract] [Full Text] [Related]

  • 17. A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome.
    Testi AM, Moleti ML, Giona F, Annino L, Chiaretti S, Del Giudice I, Todisco E, D'Elia G, Ferrari A, Arcese W, Mandelli F.
    Haematologica; 1997 Oct 01; 82(6):664-7. PubMed ID: 9499665
    [Abstract] [Full Text] [Related]

  • 18. [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
    Liu Y, Ke XY, Ma J, Shen ZX, Zhang XH, Du X, Zhao YM, Lv JQ, Zhan ZM, Zeng XY, Xu XH, Lu ZS.
    Zhonghua Zhong Liu Za Zhi; 2006 Sep 01; 28(9):706-8. PubMed ID: 17274381
    [Abstract] [Full Text] [Related]

  • 19. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia.
    Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ.
    Leuk Lymphoma; 1993 Mar 01; 9(4-5):343-50. PubMed ID: 8394169
    [Abstract] [Full Text] [Related]

  • 20. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R, Pecci A, Rossi G, Pelizzari AM, Giusto M, Tinelli C, Ascari E.
    Haematologica; 1997 Mar 01; 82(5 Suppl):9-12. PubMed ID: 9402747
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.